Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. The abstract data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Case: A 74-Year-Old Man With a History of Noninvasive Bladder Cancer

Discussion With Patient

Criteria that Render Patients Ineligible for Cisplatin

Case (cont)

Ongoing Phase 3 Adjuvant Clinical Trials

Case (cont)

Treatment Options

NCCN Preferred Options

Updates to Use of Checkpoint Inhibition in the First-Line Setting

FDA Statement on Restrictions to Use

PD-L1 Testing

Outstanding Questions on PD-L1 Testing

Follow-Up With Patient

Case Conclusion

Predictive Biomarkers

Clinical Trials in the Neoadjuvant Setting

Clinical Trials in Non-Muscle Invasive Disease

Oncologist and Urologist Working Relationship

Immune Checkpoint Inhibitors in the Second-Line Setting

Concluding Remarks

Abbreviations

Abbreviations (cont)